Our programs
Vectorized antibody pipeline
Deep expertise in vectorized antibody development
At VectorY we are experts in the field of intracellular therapeutic antibody design and adeno-associated viral (AAV) vector development. Combining this deep expertise with scalable manufacturing processes positions us uniquely for the rapid discovery and development of novel vectorized antibody treatments for neurological diseases with a high unmet medical need. Our technology overcomes the limitations of current therapeutic approaches including on delivery, durability, and target accessibility.
Treating neurodegenerative diseases
Neurodegenerative diseases affect millions of people worldwide, and this number is growing. Despite some approved treatments, there is still an immense need for new therapies that treat the underlying causes of neurodegeneration. Our current pipeline programs focus on amyotrophic lateral sclerosis (ALS), Huntington’s and Parkinson’s disease but can be expanded to additional indications including dementias. At VectorY we are determined to take therapeutic antibodies where they have never been before and bring this promising treatment option to people living with neurodegenerative diseases.
New treatment for ALS
Amyotrophic lateral sclerosis, or ALS, is a fast-progressing neurodegenerative disease for which there is no cure. Current treatments have limited effect and a high unmet medical need remains with a life expectancy after diagnosis of just 3-5 years. We believe that antibody treatments have great potential for this condition. Therefore, we are developing VTx-002 that has the potential to significantly delay disease progression and preserve quality of life in the vast majority of patients.